Regenicin EBIT

Regenicin (RGIN) currently reports a EBIT of $-630K as of September 2023. That compares with $-620K in the prior-year period — down 1.2% year over year. That is below the Industrials sector average of $41B. Use the charts on this page to explore Regenicin's EBIT history and peer comparisons.

Regenicin's EBIT decreased from $-620K to $-630K — a 1.2% year-over-year decrease (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Regenicin's EBIT of $-630K is lower than the Industrials sector average of $41B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Regenicin reported $-630K in EBIT as of September 2023. That compares with $-620K in the prior-year period — down 1.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-630K, then check the historical chart for trend and the peer comparison chart for relative positioning. The Industrials average is $41B. From there, open related valuation or income-statement pages for Regenicin, and consider following RGIN for alerts when major investors trade the stock.